6-K
Adlai Nortye Announces Oral Presentation for AN4035 Program Update at the Upcoming 38th EORTC-NCI-AACR Symposium
6-K
ADLAI NORTYE ENTERS INTO CLINICAL COLLABORATION WITH LILLY AND MERCK KGAA, DARMSTADT, GERMANY TO EVALUATE COMBINATION OF AN4035 AND CETUXIMAB
6-K
Adlai Nortye Appoints Christopher Liu, PharmD, as Head of Investor Relations and Public Relations
6-K
Adlai Nortye Group Ltd. Announces Results of Extraordinary General Meeting
6-K
Adlai Nortye Announces First Patient Dosed in Australia and U.S. FDA IND Clearance for AN4035, a First-in-Class Pan-RAS(ON) Inhibitor-Based ADC
6-K
Adlai Nortye Group Ltd. Announces 2026 Extraordinary General Meeting of Shareholders
